• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 POS filed by Renovacor Inc.

    12/1/22 5:22:39 PM ET
    $RCOR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RCOR alert in real time by email
    S-8 POS 1 brhc10044890_s8pos.htm S-8 POS
    As filed with the Securities and Exchange Commission on December 1, 2022
    Registration No. 333-263837
    Registration No. 333-261054

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, DC 20549


    POST-EFFECTIVE AMENDMENT NO. 1 TO
    Form S-8 Registration No. 333-263837
    Form S-8 Registration No. 333-261054
    UNDER THE SECURITIES ACT OF 1933
     


    RENOVACOR, INC.
    (ZEBRAFISH MERGER SUB II, LLC, AS SUCCESSOR TO RENOVACOR, INC.)
    (Exact name of registrant as specified in its charter)



    Delaware
     
    83-3169838
    (State or other jurisdiction of incorporation or organization)
     
    (IRS Employer Identification No.)
     
    201 Broadway, Suite 310
    Cambridge, Massachusetts 02139
    (610) 424-2650
    (Address, including zip code, of Principal Executive Offices)

    Renovacor, Inc. 2021 Omnibus Incentive Plan
    Renovacor, Inc. 2018 Stock Option and Grant Plan
    (Full title of the plans)


    Magdalene Cook, M.D.
    President and Chief Executive Officer
    201 Broadway, Suite 310
    Cambridge, Massachusetts 02139
    (610) 424-2650
     
    Copies to:
    John T. Haggerty
    William D. Collins
    Sarah Ashfaq
    Goodwin Procter LLP
    100 Northern Avenue
    Boston Massachusetts 02210
    (617) 570-1000
    (Name, address and telephone number of agent for service)
       



    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

    Large accelerated filer
    ☐
    Accelerated filer
    ☐
           
    Non-accelerated filer
    ☒
    Smaller reporting company
    ☒
           
       
    Emerging growth company
    ☒



    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐





    DEREGISTRATION OF SECURITIES

    This Post-Effective Amendment No. 1 (this “Post-Effective Amendment”) relates to the following Registration Statements on Form S-8 (each a “Registration Statement,” and collectively, the “Registration Statements”), filed with the Securities and Exchange Commission (the “SEC”) by Renovacor, Inc. (the “Registrant”):
     

    •
    Registration Statement No. 333-263837, filed with the SEC on March 24, 2022, pertaining to the registration of 779,396 shares of common stock of the Registrant, $0.0001 par value per share (the “Common Stock”) reserved for future issuance under the Renovacor, Inc. 2021 Omnibus Incentive Plan (the “2021 Plan”); and
     

    •
    Registration Statement No. 333-261054, filed with the SEC on November 12, 2021, pertaining to the registration of 1,119,120 shares of Common Stock reserved for future issuance under the 2021 Plan, 72,546 shares of Common Stock reserved for future issuance under the 2021 Plan to be used solely and exclusively for the grant of restricted stock units pursuant to the earnout provisions of the Agreement and Plan of Merger, dated March 22, 2021, by and among the Registrant, CHAQ2 Merger Sub, Inc., a wholly owned subsidiary of the Registrant, and Renovacor Holdings, Inc., 1,037,741 shares of Common Stock reserved for future issuance upon the exercise of previously granted stock options that remained outstanding under the 2021 Plan and 194,926 shares of Common Stock reserved for future issuance upon the exercise of previously granted stock options that remained outstanding under the 2018 Stock Option and Grant Plan.
     
    On December 1, 2022, pursuant to the terms of an Agreement and Plan of Merger (the “Merger Agreement”), dated as of September 19, 2022, by and among the Registrant, Rocket Pharmaceuticals, Inc. (“Rocket”), a Delaware corporation, Zebrafish Merger Sub, Inc. (“Merger Sub I”), a Delaware corporation and a direct wholly owned subsidiary of Rocket, and Zebrafish Merger Sub II, LLC (“Merger Sub II”), a Delaware limited liability company and a direct wholly owned subsidiary of Rocket, (i) Merger Sub I merged with and into the Registrant (the “First Merger”) and (ii) the Registrant, as the surviving company of the First Merger, merged with and into Merger Sub II (the “Second Merger” and together with the First Merger, the “Mergers”), with Merger Sub II as the surviving company and successor-in-interest to the Registrant following the Mergers, at which time the separate corporate existence of the Registrant ended. Pursuant to the requirements of the Securities Exchange Act of 1934, Merger Sub II, as successor to the Registrant, has caused this Post-Effective Amendment to be signed on its behalf by the undersigned duly authorized person.
     
    As a result of the Mergers, the Registrant has terminated any and all offerings of its securities pursuant to the Registration Statements. In accordance with an undertaking made by the Registrant in the Registration Statements to remove from registration, by means of a post-effective amendment, any of the securities registered under the Registration Statements that remain unissued at the termination of the offerings, the Registrant hereby removes from registration all securities registered but unsold under such Registration Statements, if any, as of the date hereof.
     

    SIGNATURES
     
    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Post-Effective Amendment to the Registration Statements on Form S-8 to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Cambridge, Commonwealth of Massachusetts on this 1st day of December, 2022.
     
     
    Zebrafish Merger Sub II, LLC
     
    (as successor by merger to Renovacor, Inc.)
         
     
    By:
    /s/ Gaurav Shah
     
    Name:
    Gaurav Shah
     
    Title:
    Authorized Person

    No other person is required to sign this Post-Effective Amendment in reliance upon Rule 478 under the Securities Act of 1933.
     


    Get the next $RCOR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RCOR

    DatePrice TargetRatingAnalyst
    9/13/2022$9.00Outperform
    Robert W. Baird
    10/14/2021$22.00Buy
    Ladenburg Thalmann
    10/1/2021$20.00Buy
    Chardan Capital Markets
    More analyst ratings

    $RCOR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Rockwell Medical Appoints Joan Lau, Ph.D. to the Company's Board of Directors

      Brings more than 20 years of experience as an entrepreneur scientist, CEO, operator, investor, and board member of public and private biopharmaceutical companies Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that the Company appointed Joan Lau, Ph.D. to its board of directors. Dr. Lau's appointment increases Rockwell Medical's board of directors to seven members. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231017906241/en/RMTI) (Photo: Business Wire)"

      10/17/23 6:00:00 AM ET
      $BDN
      $RMTI
      $RCOR
      Real Estate Investment Trusts
      Real Estate
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rocket Pharmaceuticals Completes Acquisition of Renovacor

      Acquisition further extends Rocket's leadership in AAV-based cardiac gene therapy and expands focus and capabilities to BAG3-associated dilated cardiomyopathy Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders with high unmet need, today announces that it has completed the previously announced acquisition of Renovacor, Inc. (NYSE:RCOR), a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases. Under the terms of t

      12/1/22 4:01:00 PM ET
      $RCKT
      $RCOR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rocket Pharmaceuticals to Acquire Renovacor, Extending Leadership in AAV-based Cardiac Gene Therapy

      Acquisition further strengthens Rocket's leadership in AAV-based cardiac gene therapy and expands Company's near-term clinical assets for the treatment of heart conditions Significant unmet medical need in BAG3-associated dilated cardiomyopathy, with meaningful commercial opportunity, comparable to Danon Disease Creates strong synergies by combining key assets, personnel, capabilities and IP, as well as access to world-leading scientific and clinical collaborators, expected to deliver long-term value for Rocket and Renovacor shareholders We believe compelling preclinical data generated by Renovacor validates mechanism of action of AAV-based transgene replacement strategy for BAG-3 di

      9/20/22 6:00:00 AM ET
      $RCKT
      $RCOR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RCOR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Rtw Investments, Lp

      4 - Renovacor, Inc. (0001799850) (Issuer)

      4/5/23 4:30:43 PM ET
      $RCOR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Needham Thomas E. Jr.

      4 - Renovacor, Inc. (0001799850) (Issuer)

      12/5/22 9:24:00 PM ET
      $RCOR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Lau Joan

      4 - Renovacor, Inc. (0001799850) (Issuer)

      12/5/22 9:23:45 PM ET
      $RCOR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RCOR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Robert W. Baird initiated coverage on Renovacor with a new price target

      Robert W. Baird initiated coverage of Renovacor with a rating of Outperform and set a new price target of $9.00

      9/13/22 7:37:19 AM ET
      $RCOR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ladenburg Thalmann initiated coverage on Renovacor with a new price target

      Ladenburg Thalmann initiated coverage of Renovacor with a rating of Buy and set a new price target of $22.00

      10/14/21 7:14:33 AM ET
      $RCOR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chardan Capital Markets initiated coverage on Renovacor with a new price target

      Chardan Capital Markets initiated coverage of Renovacor with a rating of Buy and set a new price target of $20.00

      10/1/21 7:39:25 AM ET
      $RCOR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RCOR
    SEC Filings

    See more
    • SEC Form 15-12G filed by Renovacor Inc.

      15-12G - Renovacor, Inc. (0001799850) (Filer)

      12/12/22 4:35:37 PM ET
      $RCOR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Renovacor Inc.

      EFFECT - Renovacor, Inc. (0001799850) (Filer)

      12/6/22 12:15:05 AM ET
      $RCOR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Renovacor Inc.

      EFFECT - Renovacor, Inc. (0001799850) (Filer)

      12/6/22 12:15:13 AM ET
      $RCOR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RCOR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Renovacor Inc. (Amendment)

      SC 13D/A - Renovacor, Inc. (0001799850) (Subject)

      4/5/23 4:31:54 PM ET
      $RCOR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Renovacor Inc. (Amendment)

      SC 13G/A - Renovacor, Inc. (0001799850) (Subject)

      2/14/23 7:41:31 AM ET
      $RCOR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Renovacor Inc.

      SC 13D - Renovacor, Inc. (0001799850) (Subject)

      9/21/22 9:00:09 AM ET
      $RCOR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RCOR
    Leadership Updates

    Live Leadership Updates

    See more
    • Rockwell Medical Appoints Joan Lau, Ph.D. to the Company's Board of Directors

      Brings more than 20 years of experience as an entrepreneur scientist, CEO, operator, investor, and board member of public and private biopharmaceutical companies Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that the Company appointed Joan Lau, Ph.D. to its board of directors. Dr. Lau's appointment increases Rockwell Medical's board of directors to seven members. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231017906241/en/RMTI) (Photo: Business Wire)"

      10/17/23 6:00:00 AM ET
      $BDN
      $RMTI
      $RCOR
      Real Estate Investment Trusts
      Real Estate
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Renovacor Announces the Appointment of Kumar Dhanasekharan, Ph.D., as Senior Vice President of Technical Operations

      Dr. Dhanasekharan joins Renovacor with extensive experience overseeing development, manufacturing and supply operations for biologics including AAV gene therapies Renovacor, Inc. (NYSE:RCOR), a biotechnology company developing adeno-associated virus (AAV)‑based gene therapies for devastating cardiovascular and central nervous system diseases resulting from BAG3 gene variants, today announced the appointment of Kumar Dhanasekharan, Ph.D., as Senior Vice President of Technical Operations. "With Kumar's appointment, we've added yet another innovative industry expert to Renovacor's diverse and growing leadership team," said Magdalene Cook, M.D., Chief Executive Officer of Renovacor. "Kumar is

      10/4/21 4:05:00 PM ET
      $RCOR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Renovacor Announces the Appointment of Jordan Shin, M.D., Ph.D., as Senior Vice President of Clinical Development and Translational Science

      Dr. Shin to help advance REN-001 into the clinic by leveraging nearly two decades of expertise in clinical development, academic research and medical practice Renovacor, Inc. (NYSE:RCOR), an early-stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for devastating cardiovascular and central nervous system diseases resulting from BAG3 gene variants, today announced the appointment of Jordan Shin, M.D., Ph.D., as Senior Vice President of Clinical Development and Translational Science. "We are excited to welcome Jordan to Renovacor's leadership team during this pivotal time for the company," said Magdalene Cook, M.D., Chief Executive Officer of Renovacor.

      9/22/21 4:05:00 PM ET
      $RCOR
      Biotechnology: Pharmaceutical Preparations
      Health Care